The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs, this is a vital moment for the field.

For the first time, you can join leaders from BMS, Scorpion Therapeutics, Ikena Oncology, Kronos Bio and Talus Bio at the inaugural Transcription Factor-Directed Therapies Summit, the first in-person conference on precision molecular oncology uniting experts in proteomics, genomics, structural biology, and translational sciences.

Dedicated to overcoming specific drug development challenges of targeting this ubiquitous and highly complex system with novel TPD based modalities, this unique discussion forum will equip you with the knowledge to utilize Transcription Factors as biomarkers to better predict disease prognosis and progression.

Don’t miss your chance to join fellow pioneers of Transcription Factor medicine to overcome the critical roadblocks to success in small molecule inhibitors, PROTAC-based degraders, and other therapeutic approaches targeting STAT3, c-MYC, FOXP3, p53, MITF, NF-B, and many more Transcription Factors.

Ensure your Transcription Factor program reaches full clinical potential by gaining a better understanding of the underpinning biology of the transcription regulation network and how it relates to treating disease, whilst harnessing the novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities. Join us to seek out solutions to longstanding obstacles in transcription factor therapy development at all stages, from bench to bedside.

To know more visit: https://bit.ly/3pWWEj8